SCHEMBL4705601

SCHEMBL4705601

CCn1nc(-c2ccccc2)c(C(=O)CCc2ccccc2)c(Nc2cccc(Cl)c2)c1=O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 2/20 0.53
PARP1 P09874 2/20 0.47
ACHE P22303 1/20 0.46
BACE1 P56817 1/20 0.46
PDE4A P27815 1/20 0.41
PDE4C Q08493 1/20 0.41
PDE4D Q08499 1/20 0.41
MAPT P10636 3/20 0.40
KDM4E B2RXH2 1/20 0.40
POLB P06746 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
DGAT1 O75907 1/20 0.39
KCNJ6 P48051 1/20 0.39
KCNJ5 P48544 1/20 0.39
KCNJ3 P48549 1/20 0.39
MEN1 O00255 1/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
KMT2A Q03164 1/20 0.39
PPARG P37231 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4708911 0.93 PDE4B (0.49) PDE4BPARP1ACHEBACE1PDE4A
SCHEMBL4708616 0.93 PDE4B (0.55) PDE4BPARP1ACHEBACE1PDE4A
SCHEMBL4706645 0.92 PDE4B (0.56) PDE4BPARP1ACHEBACE1PDE4A
SCHEMBL4706140 0.91 PDE4B (0.48) PDE4BPARP1ACHEBACE1PDE4A
SCHEMBL4706084 0.88 PDE4B (0.62) PDE4BPARP1ACHEBACE1PDE4A
SCHEMBL4708499 0.87 PDE4B (0.51) PDE4BACHEBACE1PDE4APDE4C
SCHEMBL4058811 0.87 PDE4B (0.70) PDE4BPARP1ACHEBACE1PDE4A
SCHEMBL4708001 0.86 PDE4B (0.54) PDE4BPARP1ACHEBACE1PDE4A
SCHEMBL4706418 0.86 PDE4B (0.60) PDE4BPARP1ACHEBACE1PDE4A
SCHEMBL4707878 0.85 PDE4B (0.53) PDE4BPARP1ACHEBACE1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7459453-B2 Pyridazin-3(2H)-one derivatives as PDE4 inhibitors LABORATORIOS ALMIRALL, S.A. (ES) 2008-12-02 US disclosed
US-20080269235-A1 PYRIDAZIN-3 (2H) -ONE DERIVATIVES AS PDE4 INHIBITORS DAL PIAZ VITTORIO 2008-10-30 US disclosed
US-20060052379-A1 Pyridazin-3(2h)-one derivatives as pde4 inhibitors LABORATORIOS ALMIRALL, S.A. (ES) 2006-03-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269235-A1 PYRIDAZIN-3 (2H) -ONE DERIVATIVES AS PDE4 INHIBITORS PDE4A, PDE3A, PDE4B PDE4B 3/4885PARP1 1082/4885ACHE 51/4885
US-20060052379-A1 Pyridazin-3(2h)-one derivatives as pde4 inhibitors PDE4A, PDE3A, PDE4B PDE4B 3/4885PARP1 1082/4885ACHE 51/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.